ArticlePolymers2026
Comparative Evaluation of β-TCP-Based Composite Biomaterials Using Chorionic Mesenchymal Stem Cells Under Non-Osteogenic Conditions.
Article in Polymers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study evaluates the intrinsic osteogenic potential of β-tricalcium phosphate (β-TCP)-containing composite scaffolds (PLCL-TCP, PLGA-TCP, and ZnO-TCP) on chorion-derived mesenchymal stem cells (CMSCs) under non-osteogenic in vitro conditions. CMSCs were cultured on the three biomaterials for 35 days without osteogenic supplements to isolate the material-driven cellular response. Cell viability was assessed via MTT assay, while osteogenesis-associated markers (alkaline phosphatase, type I collagen, and osteocalcin) were quantified using ELISA. Scaffold surface morphology and elemental composition were characterized before and after cultivation utilizing SEM and EDX. All investigated scaffolds supported long-term CMSC viability and induced measurable osteogenic responses. PLCL-TCP demonstrated a consistently strong biological response, characterized by sustained metabolic activity, elevated ALP and COL I production, and increased osteocalcin levels at later stages of cultivation. ZnO-TCP also exhibited favorable osteogenesis-associated responses, particularly with respect to late-stage osteocalcin production, while maintaining high structural stability. In conclusion, β-TCP composites can intrinsically modulate CMSC behavior without biochemical supplements. Osteogenic outcomes depend on a complex interplay of surface chemistry, scaffold architecture, and degradation profiles, with PLCL-TCP demonstrating favorable overall performance among the investigated biomaterials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.